LUIS GONZAGA
PAZ-ARES RODRÍGUEZ
Profesor titular de universidad
Centro de Investigación Biomédica en Red de Cáncer
Madrid, EspañaPublications en collaboration avec des chercheurs de Centro de Investigación Biomédica en Red de Cáncer (28)
2024
-
RET Fusion Testing in Patients With NSCLC: The RETING Study
JTO Clinical and Research Reports, Vol. 5, Núm. 4
2023
-
Aberrant Methylation of the Imprinted C19MC and MIR371-3 Clusters in Patients with Non-Small Cell Lung Cancer
Cancers, Vol. 15, Núm. 5
-
At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC
Nature Reviews Clinical Oncology, Vol. 20, Núm. 3, pp. 143-159
-
Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial
The Lancet Respiratory Medicine, Vol. 11, Núm. 1, pp. 74-86
-
Future Perspectives in the Second Line Therapeutic Setting for Non-Oncogene Addicted Non-Small-Cell Lung Cancer
Cancers, Vol. 15, Núm. 23
-
Inhibition of HSP90 in Driver Oncogene-Defined Lung Adenocarcinoma Cell Lines: Key Proteins Underpinning Therapeutic Efficacy
International Journal of Molecular Sciences, Vol. 24, Núm. 18
-
PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells
Cancer Research, Vol. 83, Núm. 15, pp. 2513-2526
-
Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer
Nature Communications, Vol. 14, Núm. 1
-
Tryptophan Modulation in Cancer-Associated Cachexia Mouse Models
International Journal of Molecular Sciences, Vol. 24, Núm. 16
2022
-
Adoptive tumor infiltrating lymphocyte transfer as personalized immunotherapy
International Review of Cell and Molecular Biology (Elsevier Inc.), pp. 163-192
-
Emerging immune checkpoint inhibitors for the treatment of non-small cell lung cancer
Expert Opinion on Emerging Drugs, Vol. 27, Núm. 3, pp. 289-300
-
SOLTI-1904 ACROPOLI TRIAL: efficacy of spartalizumab monotherapy across tumor-types expressing high levels of PD1 mRNA
Future Oncology, Vol. 18, Núm. 34, pp. 3791-3800
-
Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism
Nature medicine, Vol. 28, Núm. 4, pp. 752-765
-
Tunable gold nanorod/NAO conjugates for selective drug delivery in mitochondria-targeted cancer therapy
Nanoscale, Vol. 14, Núm. 22, pp. 8028-8040
-
YES1 Is a Druggable Oncogenic Target in SCLC
Journal of Thoracic Oncology, Vol. 17, Núm. 12, pp. 1387-1403
2021
-
An Fc-free EGFR-specific 4-1BB-agonistic trimerbody displays broad antitumor activity in humanized murine cancer models without toxicity
Clinical Cancer Research, Vol. 27, Núm. 11, pp. 3167-3177
-
LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology
Cancer Medicine, Vol. 10, Núm. 17, pp. 5878-5888
2019
-
Antitumor activity of an engineered decoy receptor targeting CLCF1–CNTFR signaling in lung adenocarcinoma
Nature Medicine, Vol. 25, Núm. 11, pp. 1783-1795
-
Necitumumab for the treatment of advanced non-small-cell lung cancer
Future Oncology, Vol. 15, Núm. 7, pp. 705-716
2018
-
Aligning digital CD8
+
scoring and targeted next-generation sequencing with programmed death ligand 1 expression: a pragmatic approach in early-stage squamous cell lung carcinoma
Histopathology, Vol. 72, Núm. 2, pp. 270-284